Svenmarker Staffan, Claesson Lingehall Helena, Malmqvist Gunnar, Appelblad Micael
Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Department of Nursing, Umeå University, Umeå, Sweden.
Perfusion. 2025 Mar;40(2):466-474. doi: 10.1177/02676591241240726. Epub 2024 Mar 21.
The study objective was to investigate whether a Ringer's acetate based priming solution with addition of Mannitol and sodium concentrate increases the risk of cardiac surgery associated kidney injury (CSA-AKI).
This is a double blind, prospective randomized controlled trial from a single tertiary teaching hospital in Sweden including patients aged ≥65 years ( = 195) admitted for routine cardiac surgery with cardiopulmonary bypass. Patients in the study group received Ringer's acetate 1000 mL + 400 mL Mannitol (60 g) + sodium chloride 40 mL (160 mmol) and heparin 2 mL (10 000 IU) 966 mOsmol ( = 98), while patients in the control group received Ringer's acetate 1400 mL + heparin 2 mL (10 000 IU), 388 mOsmol ( = 97) as pump prime. Acute kidney injury was analysed based on the Kidney Disease Improving Outcomes (KDIGO 1-3) definition.
The overall incidence of CSA-AKI (KDIGO stage 1) was 2.6% on day 1 in the ICU and 5.6% on day 3, postoperatively. The serum creatinine level did not show any postoperative intergroup differences, when compared to baseline preoperative values. Six patients in the Ringer and five patients in the Mannitol group developed CSA-AKI (KDIGO 1-3), all with glomerular filtration rates <60 mL/min/1.73 m. These patients showed significantly higher plasma osmolality levels compared to preoperative values. Hyperosmolality together with patient age and the duration of the surgery were independent risk factors for postoperative acute kidney injury (KDIGO 1-3).
The use of a hyperosmolar prime solution did not increase the incidence of postoperative CSA-AKI in this study, while high plasma osmolality alone increased the associated risk by 30%. The data suggests further examination of plasma hyperosmolality as a relative risk factor of CSA-AKI.
本研究的目的是调查添加甘露醇和浓缩钠的醋酸林格氏液预充液是否会增加心脏手术相关肾损伤(CSA-AKI)的风险。
这是一项来自瑞典一家三级教学医院的双盲、前瞻性随机对照试验,纳入年龄≥65岁(n = 195)因常规心脏手术需体外循环的患者。研究组患者接受醋酸林格氏液1000 mL + 400 mL甘露醇(60 g)+ 氯化钠40 mL(160 mmol)和肝素2 mL(10000 IU),渗透压为966 mOsmol(n = 98),而对照组患者接受醋酸林格氏液1400 mL + 肝素2 mL(10000 IU),渗透压为388 mOsmol(n = 97)作为泵预充液。根据改善全球肾脏病预后组织(KDIGO 1-3)的定义分析急性肾损伤情况。
术后第1天,ICU中CSA-AKI(KDIGO 1期)的总体发生率为2.6%,术后第3天为5.6%。与术前基线值相比,血清肌酐水平术后未显示出组间差异。林格氏液组有6例患者和甘露醇组有5例患者发生CSA-AKI(KDIGO 1-3),所有患者的肾小球滤过率均<60 mL/min/1.73 m²。与术前值相比,这些患者的血浆渗透压水平显著更高。高渗状态连同患者年龄和手术持续时间是术后急性肾损伤(KDIGO 1-3)的独立危险因素。
在本研究中,使用高渗预充液并未增加术后CSA-AKI的发生率,而仅高血浆渗透压会使相关风险增加30%。数据表明需进一步研究血浆高渗状态作为CSA-AKI相对危险因素的情况。